OptiMATe
SCC215

Phase III

Optimierung der Induktionstherapie mit MATRix (Methotrexat, Ara-C, Thiotepa, Rituximab) durch De-Eskalation bei primären 
ZNS-Lymphomen - eine randomisierte Phase III Studie

PRIME-CAR

Phase II

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (PRIME-CAR)

NCT06912529

CA073-1003
Golseek-4

Phase III

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma

 Eudract Nr. 2024-519152-82

MorningLyte

Phase III

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte)

 Eudract Nr. 2023-505436-35

CLEAR

II

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

EU-CT-Nummer:  2023-509861-19-01

BGB-16673-104

Ib/II

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

EU-CT-Nummer:  2024-516234-35